DOP2005000259A - Compuesto químico y su uso. - Google Patents
Compuesto químico y su uso.Info
- Publication number
- DOP2005000259A DOP2005000259A DO2005P000259A DO2005000259A DOP2005000259A DO P2005000259 A DOP2005000259 A DO P2005000259A DO 2005P000259 A DO2005P000259 A DO 2005P000259A DO 2005000259 A DO2005000259 A DO 2005000259A DO P2005000259 A DOP2005000259 A DO P2005000259A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- chemical compound
- prevention
- preparation
- treatment
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002265 prevention Effects 0.000 abstract 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 abstract 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000026621 hypolipoproteinemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003530 tetrahydroquinolines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004061000A DE102004061000A1 (de) | 2004-12-18 | 2004-12-18 | Chemische Verbindung und ihre Verwendung |
| DE102004060997A DE102004060997A1 (de) | 2004-12-18 | 2004-12-18 | Chemische Verbindung und ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2005000259A true DOP2005000259A (es) | 2006-11-15 |
Family
ID=35841894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2005P000259A DOP2005000259A (es) | 2004-12-18 | 2005-12-16 | Compuesto químico y su uso. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8124775B2 (https=) |
| EP (1) | EP1828137B1 (https=) |
| JP (1) | JP5132317B2 (https=) |
| KR (1) | KR20070090248A (https=) |
| AR (1) | AR055011A1 (https=) |
| AT (1) | ATE555097T1 (https=) |
| AU (1) | AU2005315770B2 (https=) |
| BR (1) | BRPI0519602A2 (https=) |
| CA (1) | CA2591397A1 (https=) |
| CU (1) | CU23452B7 (https=) |
| CY (1) | CY1112887T1 (https=) |
| DK (1) | DK1828137T3 (https=) |
| DO (1) | DOP2005000259A (https=) |
| ES (1) | ES2384980T3 (https=) |
| GT (1) | GT200500377A (https=) |
| IL (1) | IL184008A (https=) |
| MA (1) | MA29100B1 (https=) |
| MX (1) | MX2007007188A (https=) |
| NO (1) | NO20073146L (https=) |
| PE (1) | PE20060767A1 (https=) |
| PL (1) | PL1828137T3 (https=) |
| PT (1) | PT1828137E (https=) |
| RU (1) | RU2393151C2 (https=) |
| SI (1) | SI1828137T1 (https=) |
| TW (1) | TW200635900A (https=) |
| UY (1) | UY29276A1 (https=) |
| WO (1) | WO2006063828A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005324127A1 (en) * | 2004-12-18 | 2006-07-13 | Bayer Healthcare Ag | (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors |
| DE102006012548A1 (de) * | 2006-03-18 | 2007-09-20 | Bayer Healthcare Ag | Substituierte Chromanol-Derivate und ihre Verwendung |
| DK2268644T3 (da) * | 2008-03-05 | 2011-10-10 | Boehringer Ingelheim Int | Tricycliske pyridinderivater, medikamenter indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling |
| EA201201160A1 (ru) | 2010-02-19 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения |
| AU2011274903B2 (en) * | 2010-07-09 | 2016-09-08 | Daiichi Sankyo Company, Limited | Substituted pyridine compound |
| WO2012110599A1 (en) | 2011-02-17 | 2012-08-23 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| JP5947382B2 (ja) | 2011-08-17 | 2016-07-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フロ［３，４−ｃ］キノリン誘導体、このような化合物を含む薬物、それらの使用及びそれらの調製方法 |
| ES2599757T3 (es) | 2012-01-06 | 2017-02-03 | Daiichi Sankyo Company, Limited | Sales de aducto de ácido de un compuesto de piridina sustituido como inhibidores de la proteína de transferencia de ésteres de colesterilo (PTEC) |
| RU2703192C2 (ru) | 2014-07-30 | 2019-10-15 | Ф. Хоффманн-Ля Рош Аг | Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами |
| WO2025185022A1 (zh) * | 2024-03-05 | 2025-09-12 | 维康平生(北京)生物科技有限公司 | 一种脂肪体的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4128681A1 (de) * | 1991-08-29 | 1993-03-04 | Bayer Ag | Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| DE19610932A1 (de) * | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
| DE19627430A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
| HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| US6207671B1 (en) * | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
| DE19704244A1 (de) * | 1997-02-05 | 1998-08-06 | Bayer Ag | 5-Hydroxy-alkyl substituierte Phenyle |
| DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
| MA24643A1 (fr) | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
| DE19741051A1 (de) * | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
| DE19741399A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
| DE19935966A1 (de) | 1999-07-30 | 2001-02-01 | Bayer Ag | Verfahren zur Reduktion von Ketoalkoholen |
| DE10148436A1 (de) * | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
| DE10250687A1 (de) * | 2002-10-31 | 2004-05-13 | Bayer Ag | 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung |
| AU2005324127A1 (en) * | 2004-12-18 | 2006-07-13 | Bayer Healthcare Ag | (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors |
-
2005
- 2005-12-15 WO PCT/EP2005/013490 patent/WO2006063828A1/de not_active Ceased
- 2005-12-15 EP EP05820528A patent/EP1828137B1/de not_active Expired - Lifetime
- 2005-12-15 AU AU2005315770A patent/AU2005315770B2/en not_active Ceased
- 2005-12-15 US US11/793,482 patent/US8124775B2/en not_active Expired - Fee Related
- 2005-12-15 KR KR1020077016219A patent/KR20070090248A/ko not_active Ceased
- 2005-12-15 DK DK05820528.7T patent/DK1828137T3/da active
- 2005-12-15 ES ES05820528T patent/ES2384980T3/es not_active Expired - Lifetime
- 2005-12-15 CA CA002591397A patent/CA2591397A1/en not_active Abandoned
- 2005-12-15 PL PL05820528T patent/PL1828137T3/pl unknown
- 2005-12-15 MX MX2007007188A patent/MX2007007188A/es active IP Right Grant
- 2005-12-15 AT AT05820528T patent/ATE555097T1/de active
- 2005-12-15 RU RU2007127127/04A patent/RU2393151C2/ru not_active IP Right Cessation
- 2005-12-15 BR BRPI0519602-7A patent/BRPI0519602A2/pt not_active IP Right Cessation
- 2005-12-15 SI SI200531547T patent/SI1828137T1/sl unknown
- 2005-12-15 JP JP2007545948A patent/JP5132317B2/ja not_active Expired - Fee Related
- 2005-12-15 PT PT05820528T patent/PT1828137E/pt unknown
- 2005-12-16 DO DO2005P000259A patent/DOP2005000259A/es unknown
- 2005-12-16 PE PE2005001475A patent/PE20060767A1/es not_active Application Discontinuation
- 2005-12-16 AR ARP050105313A patent/AR055011A1/es not_active Application Discontinuation
- 2005-12-16 TW TW094144588A patent/TW200635900A/zh unknown
- 2005-12-19 GT GT200500377A patent/GT200500377A/es unknown
- 2005-12-20 UY UY29276A patent/UY29276A1/es not_active Application Discontinuation
-
2007
- 2007-06-18 MA MA30003A patent/MA29100B1/fr unknown
- 2007-06-18 CU CU20070140A patent/CU23452B7/es not_active IP Right Cessation
- 2007-06-18 IL IL184008A patent/IL184008A/en not_active IP Right Cessation
- 2007-06-19 NO NO20073146A patent/NO20073146L/no not_active Application Discontinuation
-
2012
- 2012-02-16 US US13/398,290 patent/US20120142728A1/en not_active Abandoned
- 2012-06-29 CY CY20121100588T patent/CY1112887T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU23452B7 (es) | 2009-12-01 |
| KR20070090248A (ko) | 2007-09-05 |
| CY1112887T1 (el) | 2016-04-13 |
| AR055011A1 (es) | 2007-08-01 |
| RU2393151C2 (ru) | 2010-06-27 |
| AU2005315770B2 (en) | 2011-12-08 |
| BRPI0519602A2 (pt) | 2009-02-25 |
| PT1828137E (pt) | 2012-07-04 |
| JP2008524145A (ja) | 2008-07-10 |
| DK1828137T3 (da) | 2012-07-23 |
| CA2591397A1 (en) | 2006-06-22 |
| AU2005315770A1 (en) | 2006-06-22 |
| ATE555097T1 (de) | 2012-05-15 |
| TW200635900A (en) | 2006-10-16 |
| US20080255068A1 (en) | 2008-10-16 |
| PL1828137T3 (pl) | 2012-09-28 |
| RU2007127127A (ru) | 2009-01-27 |
| WO2006063828A1 (de) | 2006-06-22 |
| US20120142728A1 (en) | 2012-06-07 |
| IL184008A0 (en) | 2007-10-31 |
| MA29100B1 (fr) | 2007-12-03 |
| EP1828137B1 (de) | 2012-04-25 |
| GT200500377A (es) | 2006-11-09 |
| PE20060767A1 (es) | 2006-09-10 |
| EP1828137A1 (de) | 2007-09-05 |
| ES2384980T3 (es) | 2012-07-16 |
| IL184008A (en) | 2012-03-29 |
| SI1828137T1 (sl) | 2012-08-31 |
| MX2007007188A (es) | 2007-08-14 |
| JP5132317B2 (ja) | 2013-01-30 |
| UY29276A1 (es) | 2006-07-31 |
| US8124775B2 (en) | 2012-02-28 |
| NO20073146L (no) | 2007-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2008001720A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina | |
| CL2008000785A1 (es) | Compuestos derivados de 4-((7,7-difluoro-5-metil-6-oxo-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-il)amino)-3-metoxibenzamida; compuesto intermediario; composicion farmaceutica, utiles para tratar el cancer. | |
| BRPI0915084B8 (pt) | composto, e, composição farmacêutica | |
| CL2008001457A1 (es) | Compuestos derivados de 6-(piridin-3-il)quinolina, inhibidores de la pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de cancer en un humano que lo necesite. | |
| WO2007115821A3 (en) | Organic compounds | |
| WO2009156462A3 (en) | Organic compounds | |
| CL2008002042A1 (es) | Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos. | |
| WO2007022518A3 (en) | New uses of glucoregulatory proteins | |
| CL2007000161A1 (es) | Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
| SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
| CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
| ECSP099410A (es) | Adsorbente de fosfato a base de hierro (iii)-carbohidrato | |
| CL2007002856A1 (es) | Compuestos derivados de pirazolo(1,5)pirimidina; composicion farmaceutica qu lo comprende;y su uso para tratar el cancer. | |
| CU23452B7 (es) | Derivados de tetrahidroquinolina 4-cicloalquilo sustituidos | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| CL2012000768A1 (es) | Compuestos derivados de acido l-glutamico y l-glutamina marcados con [18f]; procedimiento de preparacion; y su uso para el diagnostico de enfermedades tumorales. | |
| CL2011001331A1 (es) | Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo. | |
| CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
| CL2007003672A1 (es) | Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad. | |
| CL2007002380A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica. | |
| CL2007003038A1 (es) | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. | |
| ATE453384T1 (de) | Neue dosierformulierung | |
| EA200700982A1 (ru) | Производные хинолина и изохинолина, замещённые в 5-ом положении, способ их получения и их применение в качестве противовоспалительных средств | |
| CL2009000665A1 (es) | Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas. | |
| CL2008001719A1 (es) | Compuestos derivados de [1,10]-fenantrolina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades neurodegenerativas o hematologicas. |